Nitronal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitronal

Nitronal is a potent, prescription-only medicine used exclusively in acute, specialized care settings to manage critical cardiovascular conditions. Its identity is defined by its active ingredient, Nitroglycerin, which belongs to the class of drugs known as vasodilators.

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate, GTN)
Form Solution for intravenous infusion
Pharmacological class Vasodilator / Organic nitrate class
General purpose Reduce heart workload and strain
Origin Synthetic

What Type of Medicine is Nitronal?

Nitronal is classified as a vasodilator and an antianginal agent belonging to the organic nitrate class of synthetic pharmaceuticals. The active compound is Nitroglycerin, also known chemically as Glyceryl trinitrate (GTN). This compound functions as a nitrovasodilator, meaning its primary job is to cause the direct relaxation and widening of blood vessels.

Nitroglycerin functions as a vasodilator by relaxing the blood vessels, thereby reducing the heart’s workload and oxygen demand. This pharmacological role is clinically recognized for its rapid onset of action in situations requiring immediate hemodynamic management. Nitronal is specifically positioned for use in hospitalized adult patients where continuous, measured, and highly controllable drug delivery is essential.


Form, Composition, and General Purpose

Nitronal is supplied as a solution for infusion designed for parenteral administration, meaning it is given directly into the vein via the intravenous route. This specialized injectable preparation consists of the active substance, Nitroglycerin, dissolved within an aqueous solution base.

The general therapeutic purpose of Nitronal is to decrease the workload and strain on the heart muscle. Its core mechanism of effect centers on achieving potent venodilation, which lessens the volume of blood the heart must pump (reducing preload) and the resistance it pumps against (reducing afterload). The maximal vasodilatory effect of nitrates is exerted on venous vessels, which subsequently lowers preload and reduces myocardium workload. This controlled, rapid action is crucial for stabilizing acute circulatory issues, such as those that may occur during complex surgical procedures or hypertensive crises.

Regulatory References

  1. U.S. National Library of Medicine (NIH)

What side effects are possible with Nitronal?

Possible Side Effects and Safety Information

Nitronal (Nitroglycerin intravenous infusion) safety profile is characterized by reactions primarily linked to its potent vasodilatory action, as documented in official regulatory documents. Side effects are classified by frequency and grouped into System-Organ Classes.


Frequency-Classified Adverse Reactions

The most frequent adverse reactions are generally dose-dependent and relate to the medicine’s primary function.

Frequency Classification Officially Documented Reactions
Very Common (ge 1/10) Headache (often dose-related)
Common (ge 1/100 to < 1/10) Dizziness, Hypotension, Tachycardia, Nausea, Vomiting
Uncommon (ge 1/1,000 to < 1/100) Circulatory collapse, enhanced angina pectoris symptoms

These effects are classified across major System-Organ Classes, including Nervous System Disorders, Vascular Disorders, Cardiac Disorders, and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but serious adverse reactions and critical safety restrictions.

Serious Reactions: Potentially severe outcomes include Severe Hypotension and Methemoglobinemia, the latter being a rare, potentially life-threatening condition associated with extended high-dose exposure. Circulatory collapse is also documented as an uncommon serious event.

Safety Restrictions: The medicine is contraindicated for patients using Phosphodiesterase-5 (PDE5) inhibitors or Soluble Guanylate Cyclase (sGC) stimulators due to the risk of life-threatening hypotension. It is also restricted in patients with severe anemia and conditions involving increased intracranial pressure.

Duration and Population: Continuous infusion for longer than 12–24 hours may lead to the development of pharmacologic tolerance. Safety and efficacy have not been established for use in the pediatric population.

Overdose and Emergency Response

The official regulatory profile for Nitronal overdose defines the condition as an exaggeration of its core vasodilatory action, resulting in severe hemodynamic instability. Documented manifestations include severe symptomatic hypotension, reflex tachycardia, vertigo, syncope, and profuse sweating (diaphoresis). Overdose may also involve CNS presentations, such as a persistent throbbing headache and confusion, potentially signaling increased intracranial pressure.

A specific, life-threatening complication listed in official labeling is methemoglobinemia. This condition impairs the blood's ability to transport oxygen and requires specialized intervention. Regulator-mandated emergency actions require the immediate discontinuation of the infusion at the onset of severe signs. Urgent medical attention must be sought immediately for symptoms of profound hypotension, cardiovascular collapse, or any indication of impaired oxygen delivery.

No specific pharmacological antidote is documented for the general effects of nitrate overdose; management is symptomatic and supportive, primarily focusing on intravenous fluid administration to restore blood pressure. For confirmed methemoglobinemia, Methylene Blue is the designated treatment listed in official prescribing information. The regulatory labels note that managing overdose in patients with existing heart failure or renal disease requires careful and potentially invasive monitoring.

Therapeutic Uses of Nitronal

What Nitronal Treats: Main Uses and Benefits

This medication is applied in clinical settings that involve acute or unstable symptom patterns related to the cardiovascular system.

Nitronal is commonly used to help with managing acute manifestations across three primary areas: to address severe ischemic chest pain in acute coronary syndromes, to manage symptoms of decompensated heart failure, and for the control of severe blood pressure elevations during crises or high-risk procedures.

The benefit is rooted in providing support that helps ease the overall symptom burden during these critical episodes. The goal is supportive relief:

“The infusion is applied when symptoms create noticeable functional strain and additional symptomatic support is needed.”

This assistance contributes to improved comfort during these severe episodes, particularly those involving high vascular pressures or pronounced breathing difficulties.


Quick Fact: Relief for Severe Cardiovascular Symptoms Used in acute care to manage symptoms linked to organ-specific functional stress, assist with functional stability, and help ease overall patient distress during a crisis.

Regulatory References

  1. U.S. Food and Drug Administration (FDA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitronal?

The population eligibility for intravenous Nitroglycerin (Nitronal) is strictly defined by regulatory documents, distinguishing between those permitted for use, those with restrictions, and those for whom the medicine is absolutely contraindicated.

Absolute Contraindications

Nitronal must not be used in patients with:

  • Known hypersensitivity to nitroglycerin, nitrates, or nitrites.
  • Concurrent use of Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) or the sGC stimulator riociguat.
  • Conditions that significantly raise intracranial pressure (e.g., cerebral hemorrhage).
  • Severe conditions where cardiac output depends on venous return, such as pericardial tamponade or restrictive cardiomyopathy.
  • Severe anemia or uncorrected hypovolemia.

Eligibility and Restriction Status

Population Group Regulatory Status
Adults Established eligibility and primary target population.
Pediatric Patients Safety and effectiveness not established; use is not recommended.
Pregnancy/Lactation Inadequate human data; use only if clearly needed.
Severe Organ Impairment Use requires caution and monitoring in patients with severe hepatic or renal impairment or pre-existing hypotension.

What should I know about interactions with other medicines?

Nitronal (Nitroglycerin) has documented interaction patterns that primarily involve pharmacodynamic potentiation and specific modifications to the exposure of co-administered substances, as stated in regulatory labels.

Interaction Classification Interacting Agents / Classes Official Outcome
Formally Contraindicated PDE-5 Inhibitors (e.g., Sildenafil); sGC Stimulators (e.g., Riociguat) Risk of severe hypotension, syncope, or myocardial ischemia.
Pharmacodynamic Other Antihypertensives (e.g., Beta-blockers, CCBs); Alcohol (Ethanol); NSAIDs Additive vasodilatory effects leading to potentiated hypotension. NSAIDs may diminish the therapeutic response.
Exposure Alteration Heparin (IV); Alteplase; Dihydroergotamine Reduces anticoagulant/thrombolytic effect; Increases Dihydroergotamine exposure.

The regulatory profile strictly prohibits co-administration with PDE-5 inhibitors and sGC stimulators due to the severe, potentially life-threatening pharmacodynamic potentiation. Intravenous Nitronal reduces the anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase, a clinically significant interaction requiring monitoring of APTT (Activated Partial Thromboplastin Times). Furthermore, the official documentation establishes mandatory procedural constraints for the infusion itself: the solution must not be mixed with other medications in the infusion set, nor can it be administered with blood products due to the risk of physical incompatibility. Concomitant use with alcohol may also enhance hypotensive sensitivity. Oral forms also increase the exposure of Dihydroergotamine by altering its first-pass metabolism.

Mechanism of Action

Nitronal (Nitroglycerin) exerts its effect through a two-step process that leads to widespread smooth muscle relaxation, relying on the body's natural signaling machinery.


Molecular Activation via Enzymatic Reduction

The drug begins as an inactive compound, or prodrug, which must be biologically converted to its active form. This critical first step occurs inside the cell, where the mitochondrial enzyme Aldehyde Dehydrogenase (ALDH2) acts on Nitroglycerin, facilitating the release of the gaseous signaling molecule Nitric Oxide (NO). This enzymatic activation is essential because the subsequent physiological effects are entirely dependent on the successful generation of NO.


NO-cGMP Pathway and Vascular Smooth Muscle Relaxation

The generated Nitric Oxide then targets the enzyme Soluble Guanylate Cyclase (sGC), triggering the production of the second messenger cyclic GMP (cGMP). Elevated cGMP levels ultimately cause the key proteins responsible for muscle contraction (myosin light chains) to be deactivated, resulting in the relaxation of vascular smooth muscle. This direct action modulates vascular tone and increases the capacity of the blood vessels.


Hemodynamic Modulation of Cardiac Workload

The primary physiological consequence of this vasodilation is a preferential widening of the veins (venodilation), which reduces the volume of blood returning to the heart. This reduction in the heart’s filling pressure (preload) and, to a lesser extent, the resistance it pumps against (afterload), directly reduces overall myocardial wall tension.

Dosage and Administration Information

Official Administration Guidelines for Nitroglycerin (Nitronal)

These instructions define the use of nitroglycerin, covering acute, prophylactic, and continuous administration methods.

Route Dosage Form Primary Usage Rule
Sublingual/Lingual Tablet, Powder, Spray Acute Relief Dosing: Take one dose at the onset of pain. Repeat every 5 minutes up to a maximum of 3 doses in a 15-minute period.
Transdermal Patch, Ointment Prophylaxis Schedule: Administer on a daily, cyclical schedule that includes a mandatory 10 to 14 hour drug-free interval to prevent tolerance.
Intravenous (IV) Solution Continuous Infusion: Initiated at 5 mu g/min and administered via a continuous infusion pump.

Procedural Administration Requirements

Acute Sublingual Use: The patient must be sitting down before and after administration. Sublingual tablets or powders must be placed under the tongue and allowed to dissolve completely; they must not be chewed, swallowed, or crushed. The lingual spray must be aimed onto or under the tongue, and the patient must not inhale the spray.

IV Preparation: The injection concentrate must be diluted in Dextrose 5% or Sodium Chloride 0.9% injection before infusion. The infusion must be administered using non-adsorbing (non-PVC) administration sets due to potential drug loss to certain plastics.

Topical/Transdermal Use: Apply the patch or ointment to a clean, hairless area of the skin. The application site should be rotated daily. The patch or ointment should be removed according to the daily schedule to ensure the mandatory drug-free interval is observed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Varenicline


Evidence for use in Smoking Cessation

Varenicline was evaluated in research exploring how symptoms change over time, primarily through Randomized Controlled Trials (RCTs). These studies generally included adult smokers who were seeking to achieve abstinence. Researchers monitored outcomes related to physical discomfort and outcomes reflecting daily functioning, specifically measuring how often patients achieved abstinence from smoking at defined time intervals, such as 6 months or 1 year. The research also examined scores related to cravings and nicotine withdrawal symptoms.

Findings describe patterns observed in these studies, where differences in the reported measurements of abstinence were observed between the study groups and those who received an inactive substance (placebo). Studies monitored differences in cravings and withdrawal symptoms across the groups. This evidence contributes to understanding symptom patterns in populations included in studies of varenicline for smoking cessation.

However, long-term effects are not fully established; there is limited information available for outcomes sustained beyond one year. The evidence quality varies across studies due to factors such as differences in how abstinence was measured (e.g., whether it was biochemically verified), and the existing research provides limited insight.


Evidence for use in Reduction in Heavy Drinking (AUD)

Varenicline was evaluated in research settings that included individuals diagnosed with Alcohol Use Disorder (AUD), a condition characterized by fluctuating or episodic manifestations of alcohol consumption. Research was conducted during periods of increased symptom activity (heavy drinking) and explored short-term symptom changes. The research examined outcomes describing episodic or acute changes, primarily focusing on the change in the percentage of heavy drinking days (PHDD) and overall alcohol consumption over short, defined time intervals, typically between 12 and 16 weeks.

The research highlights changes measured during the short study period. Studies report how symptoms evolved in the observed populations, studies observed different patterns in the measured outcomes related to heavy drinking days between the group receiving varenicline and the control group. These findings help contextualize how patients reported their experience during the short period the treatment was evaluated.

Evidence for this indication is limited, and data are still emerging. Follow-up durations were limited, providing little insight into long-term outcomes beyond the short treatment period. Additionally, evidence quality varies across studies, and findings were sometimes mixed. The data for certain patient groups, especially those with severe or complicated AUD, remain insufficient.


Long-term Studies and Follow-up

Research has explored outcomes beyond the initial treatment duration, particularly for smoking cessation. Studies monitored patterns in patients over intermediate follow-up periods, such as 6 months to 1 year after the treatment was completed. This evidence contributes to the broader evidence landscape by providing context on measurements documented after the treatment period was completed.

However, long-term effects are not fully established. There is limited information for long-term outcomes, especially for alcohol use reduction and for many special populations. The available evidence applies only to the populations studied and does not determine whether an individual will sustain results over many years.


Evidence in Special Populations

Varenicline was evaluated in some studies involving populations with comorbid conditions. For instance, research examined its use in smokers who also had other health conditions present in the study populations, such as cardiovascular disease or psychiatric conditions. These studies were applied in research contexts involving fluctuating or unstable symptoms related to their comorbidities while evaluating smoking cessation outcomes.

Findings help contextualize how patients reported their experience in these more complex settings. For example, some studies monitored how symptoms evolved in patients with psychiatric conditions and reported patterns related to both smoking abstinence and psychiatric symptoms. However, sample sizes were modest in these specific subgroup analyses, meaning the results apply only to the populations studied. Data for certain groups, such as adolescents or pregnant individuals, remain insufficient, and comparative evidence for these specific subgroups is lacking.


What is Still Uncertain about Varenicline

Research is ongoing, and there are several areas where the evidence landscape is still developing. Evidence for some study outcomes is limited, particularly concerning long-term follow-up beyond one year across both indications. The available data are still emerging for certain subgroups, and findings were sometimes mixed or based on studies where sample sizes were modest.

The data show patterns related to outcomes observed in the studies; however, research findings describe group patterns, not personal outcomes. The evidence highlights what is known—that specific short-term changes were measured—and what is still uncertain, which includes the durability of these outcomes and the full applicability of the findings to all patient groups, especially those with severe or complex comorbid conditions.

Key Studies & References

  1. Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression
  2. Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial

Frequently Asked Questions (FAQ)

Common questions about Nitronal (FAQ)

Q: Is Nitronal considered a long-term or short-term treatment?

Nitroglycerin is approved for use in two primary ways, according to official product information. It is used for the acute relief of sudden chest pain, which is considered a short-term use. It is also used prophylactically (for prevention) on a long-term, cyclical schedule for chronic conditions, though a mandatory drug-free interval is required daily to prevent the body from developing tolerance.


Q: Is it true that Nitronal can only be used by adults?

Regulatory documents indicate that the safety and effectiveness of Nitroglycerin have not been established for use in the pediatric population. Therefore, its use is primarily established for the adult population. The safety and efficacy profile has not been established for the pediatric population, and the medicine is generally reserved for adult use.


Q: What are the most common side effects reported for Nitronal?

The official product labeling reports that the most frequent adverse reactions are often dose-related. These common effects include headache, which is very common, along with dizziness and hypotension (low blood pressure). These are generally linked to the medicine's primary action of widening blood vessels.


Q: Is the feeling of flushing a normal side effect of Nitronal?

Yes, official patient information documents that flushing (a feeling of warmth or redness in the face or neck) is a known side effect of the medicine. This sensation is directly related to the vasodilation, or widening of blood vessels, that the medication causes in the body.


Q: What happens if I stop taking Nitronal suddenly?

For any medication used to manage a heart condition, abruptly stopping treatment may be associated with a worsening of your existing symptoms or a potential rebound effect. Regulatory guidance often focuses on preventing tolerance during continuous use. Discontinuing treatment is a process that is typically managed under the direction of a healthcare professional.


Q: Is Nitronal suitable for people with pre-existing kidney issues?

Nitroglycerin is mostly processed by the liver, meaning dose adjustments are generally not required for patients with kidney failure. However, official information advises that caution and monitoring are necessary for individuals with severe renal impairment or those who are volume-depleted, as they may be more sensitive to the medicine's effects.


Q: Can Nitronal be taken at the same time as cold and flu medicine?

The regulatory documents indicate that co-administration of all medications and supplements should be noted by a healthcare provider. Some common ingredients in cold and flu medicines, such as certain antihistamines, can cause dry mouth. This may interfere with how quickly the sublingual tablets dissolve under the tongue.


Q: Are there different strengths or forms of Nitronal available?

Yes, the active ingredient Nitroglycerin is available in various dosage forms beyond the intravenous solution. These include sublingual tablets for acute relief, oral spray, extended-release capsules, and transdermal patches, each offered in different strengths.


Q: What should I do if I think I missed a dose of Nitronal?

For scheduled forms of the medicine, such as long-acting capsules, the dose is taken as soon as it is remembered. If it is almost time for the next scheduled dose, regulatory instructions typically state that the missed dose is usually omitted. Official guidance often indicates that a double dose should not be taken to compensate for a single missed dose.


Q: Does Nitronal have any known food or drink restrictions?

Official patient information generally advises continuing a normal diet unless a healthcare provider directs otherwise. However, there is a specific warning regarding the use of alcohol, as it can increase the risk of side effects, particularly low blood pressure.


Q: Why is it important to tell my doctor about all supplements I take with Nitronal?

Official labels advise that co-administration of supplements be noted, as the medication has the potential to interact with many other substances. Some products can cause dangerously low blood pressure, while others, such as certain pain relievers, may reduce the therapeutic effect of the medicine.


Q: Is there a maximum amount of time a person is expected to use Nitronal?

For acute chest pain relief, the maximum limit described is three doses within a 15-minute period. For chronic continuous use (e.g., intravenous infusion), the development of tolerance, which is a loss of the medicine’s effectiveness over time, is documented to occur after 12 to 24 hours.


Q: Does Nitronal carry a risk of dependence or addiction?

Official documentation does not list addiction or classic dependence as a recognized risk of the medication. The primary concern for long-term use is the potential to develop tolerance, where the body loses its responsiveness to the drug's effects over time.


Q: What does the research say about Nitronal's effectiveness for its approved uses?

The regulatory designation of this medicine for its approved indications, such as the relief of angina, is based on clinical evidence, including Randomized Controlled Trials (RCTs). This research supports its designation and observed patterns of rapid therapeutic relief and prophylaxis.


Q: Are there any large-scale studies supporting the use of Nitronal?

Yes, the established use of Nitroglycerin is supported by extensive clinical trials and long-standing clinical experience. This body of evidence documents observed patterns of effect and supports its use for approved indications.


Q: Does taking Nitronal require regular blood tests?

Routine blood tests are not generally required for most typical uses of this medicine. However, close monitoring by a doctor is important, and specific tests (such as monitoring APTT) are required if the intravenous form is administered with Heparin.


Q: What are the ingredients in Nitronal besides the active one?

In addition to the active drug, Nitroglycerin, the various formulations contain inactive ingredients (excipients). For example, the tablets may contain substances such as lactose monohydrate or silicon dioxide, as listed in the official product description.


Q: Why do some users report a burning or tingling sensation with Nitronal?

The official label notes that the medicine may produce a burning or tingling sensation when administered sublingually (under the tongue). This sensation is a recognized and expected local effect of the drug.


Q: What should I avoid doing while the effects of Nitronal are peaking?

To prevent dizziness and fainting due to potential low blood pressure, official instructions describe the need to sit down before administration and recommend caution when transitioning quickly from a sitting or lying position to a standing position.


Q: Does Nitronal interact with common anti-anxiety or sleeping pills?

Official patient information cautions that certain medications, including some antidepressants and antihistamines (often found in sleeping aids), can cause a dry mouth. A dry mouth can interfere with how the sublingual tablets dissolve and work as intended.


Q: Why is Nitronal sometimes given in a hospital setting?

The intravenous form of Nitroglycerin is indicated for managing acute, critical conditions that require continuous, measured drug delivery. These uses include treating severe, unstable chest pain, acute congestive heart failure after a heart attack, and hypertension during surgical procedures.


Q: What kind of specialist usually prescribes Nitronal?

Given its uses for acute and complex heart conditions, the medication is typically managed by specialists in cardiology (heart doctors) or by physicians overseeing patients in critical care or specialized hospital settings.


Q: What is the typical age range of people who are prescribed Nitronal?

The primary population group for whom the medicine is established is adults. The official documentation also contains specific warnings and cautions for elderly patients (65 and over), indicating that older adults are a significant part of the population that uses this medicine.


Q: Are there any warnings about using Nitronal before surgery?

Official patient information indicates that a patient's healthcare provider or dentist should be aware of the medication use if any surgical procedure is planned, including dental surgery.

How should Nitronal be stored and disposed of?

How to Store and Dispose of Nitronal?

Official Storage Requirements

Nitronal (nitroglycerin) must be stored at Controlled Room Temperature, typically 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). To maintain stability and potency, the medication requires protection from excess heat, moisture, and direct sunlight.

Handling and Container Rules

Certain formulations, such as sublingual tablets, must be kept in their original, tightly-capped glass container to prevent loss of potency. Spray formulations are in a pressurized container and are flammable; they must not be forcefully opened, burned, or sprayed toward any flames. Keep the medication in a secure place out of the reach of children.

Disposal Instructions

Any outdated or unneeded Nitronal should be safely discarded according to local waste regulations. Used transdermal patches should be folded in half, sticky sides together, before disposal to ensure they are kept out of the reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitronal found in:

A-Z Index: